Anthelmintic Drugs Market by Drug Class (Benzimidazoles, Piperazine, Imidazothiazole, Spiroindoles, Others) by Route of Administration (Oral, Injectable) by Application (Human, Animal) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Veterinary Pharmacies, Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2020 – 2026

Published Date: 23-Feb-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-5853 Status : Published

The anthelmintic drugs market is set for a rapid growth over the forecast period. In terms of revenue, the global Anthelmintic Drugs market accounted for USD 2,149.7 Million in 2019 and is expected to reach USD 3,142.7 Million by 2026, growing at a CAGR of 5.57%

Description

The anthelmintic drugs market is set for a rapid growth over the forecast period. In terms of revenue, the global Anthelmintic Drugs market accounted for USD 2,149.7 Million in 2019 and is expected to reach USD 3,142.7 Million by 2026, growing at a CAGR of 5.57%

Global Anthelmintic Drugs Market: Overview

Anthelmintics is a group of parasitic drugs that extract parasitic worms (helminths) and other internal parasites from the body either by stunning or destroying them and without causing any damage to the host. They can also be referred to as vermifuges or vermicides. Anthelmintics is used to treat people who are diagnosed with helminths, an infection called helminthiasis. These medications are also used for the treatment of infected animals. The parasites are of considerable significance for tropical human medicine and veterinary medicine.

The World Health Organization reports that 2 billion people carry parasitic worm infections that cause increased mortality and morbidity, whereas parasitic worms that infect livestock is a critical animal welfare problem and pose a massive economic strain on food production. Domestic pets are also vulnerable to parasitic worm infection, and it should be noted that the companion animal industry is a key economic concern for animal welfare firms involved in drug development programmes.

Global Anthelmintic Drugs Market: Growth Factors

Effective use of anthelmintics in children is of significant public health interest since the parasites involved are likely to infect more than 2 billion people, most of whom are particularly prevalent and harmful in children. Properly targeted drug delivery, especially through community chemotherapy, can dramatically reduce aggregate mortality and morbidity as well as boost growth rates, physical activity and fitness, cognitive and academic performance and social well-being.

There are a variety of anthelmintics available for the management of gastrointestinal nematodes in cattle. Ostertagia ostertagi, lung worm, Fasciola hepatica, and Cooperia spp., are likely to cause the greatest losses in production in North America. Clorsulon is a fresh, safe anthelmintic that offers good control of the fluke of the liver and thus fills a void in control of cattle helminths in North America. The accurate use of anthelmintics in conjunction with management based on knowledge of parasite epidemiology will ensure that cattle are not easily reinfected. In this way, the advantages of the use of anthelmintics can be very substantial and much higher than the control costs.

Impact due to the outbreak of COVID-19

The ongoing outbreak of COVID-19 (coronavirus) created an alarming situation for medicines that could fend off a novel infection. Thus, AI (Artificial Intelligence) Gero is gaining worldwide recognition for specializing in AI-driven drug development and validating the promising potential of anthelmintic drugs for the treatment of COVID-19. Niclosamide is known to be relatively useful in the treatment of coronavirus in patients and has been approved in the United States, France, Italy and few other places where there is an increasing incidence of active COVID-19 patients.

As a result of the approval of niclosamide, businesses in the anthelmintic drug industry are increasing their effectiveness in AI-driven drug discovery approaches to focus on revenue generation prospects. Companies in the anthelmintic drugs industry are making efforts to perform clinical trials of existing drugs that could be useful in coronavirus medication.

Global Anthelmintic Drugs Market: Segmentation

Piperazine belongs to the family of antihelminthic drug that effectively blocks the cholinergic neuromuscular receptors in worms. It is easily consumed, but has an extremely unstable half-life.  In the treatment of ascariasis, the adult oral intake of 4 grams of piperazine hydrate has been widely used. In most developed countries, it has been discontinued, largely due to concerns about potential carcinogenicity and electroencephalographic changes.

Piperazine does not cause adverse effects in most patients. There may be mild gastrointestinal disturbances; neurotoxicity is uncommon. Lacrimation, eczematous skin reactions, rhinorrhea, productive cough, joint pains, and bronchospasm can develop following sensitization, particularly with occupational exposure.

Benzimidazole is a heterocyclic compound formed from a ring of benzene and imidazole containing oxygen sulphur, nitrogen and its derivatives are of broad interest, both in terms of their inhibitory activity and their favorable selectivity ratio, due to their diverse clinical applications and biological activity.

The identified nucleus is a vitamin-B12 constituent. Benzimidazoles are known to be a promising class of bioactive heterocyclic compounds with a number of biological activities, such as anti-viral, anti-microbial, anti-diabetic, anti-oxidant, anti-cancer, anti-parasitic, anti-proliferative, anti-helminthic, anti-viral, and anti-HIV among others. Benzimidazoles demonstrate substantial activity as potential antitumor agents, intestinal cystitis therapy, smooth cell proliferation inhibitors, and in a number of areas of chemistry.

Global Anthelmintic Drugs Market: Regional Analysis

By Geography, the anthelmintic drugs market is segmented into North America, Europe, Latin America, Asia Pacific, and Middle East and Africa.

Europe accounted for the largest market for anthelmintic drugs in 2019, followed by Asia Pacific. The number of pet animals in the region is growing at a higher rate than that of livestock, leading to an increase in pet ownership, thereby the involvement of key players supplying anthelmintic drugs is also progressing. This, in turn, is expected to improve the growth of anthelmintic drugs market in the region.

The demand for anthelmintic drugs in Asia Pacific is likely to grow to the highest CAGR from 2020 to 2026. The growth of the market in the region can be attributed to a wide veterinary sector in China, New Zealand and Australia. Growing expenditure on pet care; increasing demand for animal care; and rising demand for veterinary hospitals and clinics in India, China, South Korea, and Hong Kong are some of the factors boosting the demand for anthelmintic drugs in the region.

Global Anthelmintic Drugs Market: Competitive Players

The major players in the global anthelmintic drugs market include Novartis AG, Cipla Inc., Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.), Zoetis, Inc., GlaxoSmithKline plc, Bayer AG, Merck & Co., Inc. (Intervet Inc.), and Boehringer Ingelheim International GmbH among others.

The report segment of global anthelmintic drugs market are as follows:

Global Anthelmintic Drugs Market: Drug Class Segment Analysis

  • Benzimidazoles
  • Piperazine
  • Imidazothiazole
  • Spiroindoles
  • Others

Global Anthelmintic Drugs Market: Route of Administration Segment Analysis

  • Oral
  • Injectable

Global Anthelmintic Drugs Market: Application Segment Analysis

  • Human
  • Animal        

Global Anthelmintic Drugs Market: Distribution Channel Segment Analysis

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Veterinary Pharmacies
  • Others

Global Anthelmintic Drugs Market: Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description
      • 1.1.1. Objective
      • 1.1.2. Target Audience
      • 1.1.3. Unique Selling Proposition (USP) & Offerings
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodulogy
      • 1.3.3. Level 1: Primary Research
      • 1.3.4. Level 2: Secondary Research
      • 1.3.5. Level 3: Data Validation and Expert Panel Assessment Report Description and Scope
  • Chapter 2. Executive Summary
    • 2.1. Global Anthelmintic Drugs Market, 2016-2026, (USD Million)
    • 2.2. Anthelmintic Drugs Market: Market snapshot
  • Chapter 3. Global Anthelmintic Drugs Market – Industry Analysis
    • 3.1. Introduction
    • 3.2. Industry ecosystem analysis
    • 3.3. Route of Administration landscape
    • 3.4. Market Drivers
      • 3.4.1. North America
      • 3.4.2. Europe
      • 3.4.3. Asia Pacific
      • 3.4.4. Latin America
      • 3.4.5. MEA
    • 3.5. Restraints
    • 3.6. Opportunity
    • 3.7. Innovation & sustainability
    • 3.8. Regulatory landscape
    • 3.9. Porter’s Five Forces Analysis
    • 3.10. PESTLE Analysis
    • 3.11. Anthelmintic Drugs Market: Market Attractiveness Analysis
      • 3.11.1. Market Attractiveness Analysis by Drug Class Segment
      • 3.11.2. Market Attractiveness Analysis by Route of Administration Segment
      • 3.11.3. Market Attractiveness Analysis by Application Segment
      • 3.11.4. Market Attractiveness Analysis by Distribution Channel Segment
  • Chapter 4. Global Anthelmintic Drugs Market - Competitive Landscape
    • 4.1. Company Market Share Analysis, 2019
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions and Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Cullaborations and Joint Ventures
      • 4.2.4. Research & Development and Regional Expansion
  • Chapter 5. Anthelmintic Drugs Market – Drug Class Segment Analysis
    • 5.1. Global Anthelmintic Drugs Market Revenue Share, by Drug Class, 2019 & 2026 (USD Million)
    • 5.2. Global Anthelmintic Drugs Market by Benzimidazules, 2016 – 2026 (USD Million)
    • 5.3. Global Anthelmintic Drugs Market by Piperazine, 2016 – 2026 (USD Million)
    • 5.4. Global Anthelmintic Drugs Market by Imidazothiazule, 2016 – 2026 (USD Million)
    • 5.5. Global Anthelmintic Drugs Market by Spiroindules, 2016 – 2026 (USD Million)
    • 5.6. Global Anthelmintic Drugs Market by Others, 2016 – 2026 (USD Million)
  • Chapter 6. Anthelmintic Drugs Market – Route of Administration Segment Analysis
    • 6.1. Global Anthelmintic Drugs Market Revenue Share, by Route of Administration, 2019 & 2026 (USD Million)
    • 6.2. Global Anthelmintic Drugs Market by Oral, 2016 – 2026 (USD Million)
    • 6.3. Global Anthelmintic Drugs Market by Injectable, 2016 – 2026 (USD Million)
  • Chapter 7. Anthelmintic Drugs Market – Application Segment Analysis
    • 7.1. Global Anthelmintic Drugs Market Revenue Share, by Application, 2019 & 2026 (USD Million)
    • 7.2. Global Anthelmintic Drugs Market by Human, 2016 – 2026 (USD Million)
    • 7.3. Global Anthelmintic Drugs Market by Animal, 2016 – 2026 (USD Million)
  • Chapter 8. Anthelmintic Drugs Market – Distribution Channel Segment Analysis
    • 8.1. Global Anthelmintic Drugs Market Revenue Share, by Distribution Channel, 2019 & 2026 (USD Million)
    • 8.2. Global Anthelmintic Drugs Market by Hospital Pharmacies, 2016 – 2026 (USD Million)
    • 8.3. Global Anthelmintic Drugs Market by Retail Pharmacies, 2016 – 2026 (USD Million)
    • 8.4. Global Anthelmintic Drugs Market by Online Pharmacies, 2016 – 2026 (USD Million)
    • 8.5. Global Anthelmintic Drugs Market by Veterinary Pharmacies, 2016 – 2026 (USD Million)
    • 8.6. Global Anthelmintic Drugs Market by Others, 2016 – 2026 (USD Million)
  • Chapter 9. Anthelmintic Drugs Market - Regional Analysis
    • 9.1. Global Anthelmintic Drugs Market: Regional Overview
      • 9.1.1. Global Anthelmintic Drugs Market Revenue Share, By Region, 2019 & 2026 (USD Million)
    • 9.2. North America
      • 9.2.1. North America Anthelmintic Drugs Market Revenue 2016 – 2026 (USD Million)
      • 9.2.2. North America Anthelmintic Drugs Market Revenue, By Drug Class, 2016 – 2026 (USD Million)
      • 9.2.3. North America Anthelmintic Drugs Market Revenue, By Route of Administration, 2016 – 2026 (USD Million)
      • 9.2.4. North America Anthelmintic Drugs Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.2.5. North America Anthelmintic Drugs Market Revenue, By Distribution Channel, 2016 – 2026 (USD Million)
      • 9.2.6. U.S.
        • 9.2.6.1. U.S. Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.2.6.2. U.S. Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.2.6.3. U.S. Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.2.6.4. U.S. Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.2.7. Canada
        • 9.2.7.1. Canada Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.2.7.2. Canada Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.2.7.3. Canada Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.2.7.4. Canada Education & Learning Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.2.8. Mexico
        • 9.2.8.1. Mexico Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.2.8.2. Mexico Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.2.8.3. Mexico Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.2.8.4. Mexico Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
    • 9.3. Europe
      • 9.3.1. Europe Anthelmintic Drugs Market Revenue 2016 – 2026 (USD Million)
      • 9.3.2. Europe Anthelmintic Drugs Market Revenue, By Drug Class, 2016 – 2026 (USD Million)
      • 9.3.3. Europe Anthelmintic Drugs Market Revenue, By Route of Administration, 2016 – 2026 (USD Million)
      • 9.3.4. Europe Anthelmintic Drugs Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.3.5. Europe Anthelmintic Drugs Market Revenue, By Distribution Channel, 2016 – 2026 (USD Million)
      • 9.3.6. UK
        • 9.3.6.1. UK Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.3.6.2. UK Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.3.6.3. UK Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.3.6.4. UK Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.3.7. France
        • 9.3.7.1. France Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.3.7.2. France Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.3.7.3. France Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.3.7.4. France Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.3.8. Germany
        • 9.3.8.1. Germany Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.3.8.2. Germany Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.3.8.3. Germany Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.3.8.4. Germany Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.3.9. Italy
        • 9.3.9.1. Italy Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.3.9.2. Italy Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.3.9.3. Italy Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.3.9.4. Italy Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.3.10. Spain
        • 9.3.10.1. Spain Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.3.10.2. Spain Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.3.10.3. Spain Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.3.10.4. Spain Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.3.11. Russia
        • 9.3.11.1. Russia Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.3.11.2. Russia Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.3.11.3. Russia Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.3.11.4. Russia Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.3.12. Rest of Europe
        • 9.3.12.1. Rest of Europe Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.3.12.2. Rest of Europe Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.3.12.3. Rest of Europe Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.3.12.4. Rest of Europe Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Anthelmintic Drugs Market Revenue 2016 – 2026 (USD Million)
      • 9.4.2. Asia Pacific Anthelmintic Drugs Market Revenue, By Drug Class, 2016 – 2026 (USD Million)
      • 9.4.3. Asia Pacific Anthelmintic Drugs Market Revenue, By Route of Administration, 2016 – 2026 (USD Million)
      • 9.4.4. Asia Pacific Anthelmintic Drugs Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.4.5. Asia Pacific Anthelmintic Drugs Market Revenue, By Distribution Channel, 2016 – 2026 (USD Million)
      • 9.4.6. China
        • 9.4.6.1. China Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.4.6.2. China Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.4.6.3. China Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.4.6.4. China Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.4.7. Japan
        • 9.4.7.1. Japan Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.4.7.2. Japan Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.4.7.3. Japan Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.4.7.4. Japan Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.4.8. India
        • 9.4.8.1. India Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.4.8.2. India Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.4.8.3. India Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.4.8.4. India Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.4.9. Australia
        • 9.4.9.1. Australia Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.4.9.2. Australia Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.4.9.3. Australia Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.4.9.4. Australia Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.4.10. South Korea
        • 9.4.10.1. South Korea Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.4.10.2. South Korea Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.4.10.3. South Korea Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.4.10.4. South Korea Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.4.11. Rest of Asia Pacific
        • 9.4.11.1. Rest of Asia Pacific Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.4.11.2. Rest of Asia Pacific Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.4.11.3. Rest of Asia Pacific Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.4.11.4. Rest of Asia Pacific Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America Anthelmintic Drugs Market Revenue 2016 – 2026 (USD Million)
      • 9.5.2. Latin America Anthelmintic Drugs Market Revenue, By Drug Class, 2016 – 2026 (USD Million)
      • 9.5.3. Latin America Anthelmintic Drugs Market Revenue, By Route of Administration, 2016 – 2026 (USD Million)
      • 9.5.4. Latin America Anthelmintic Drugs Market Revenue, By Application, 2016 – 2026 (USD Million)
      • 9.5.5. Latin America Anthelmintic Drugs Market Revenue, By Distribution Channel, 2016 – 2026 (USD Million)
      • 9.5.6. Brazil
        • 9.5.6.1. Brazil Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.5.6.2. Brazil Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.5.6.3. Brazil Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.5.6.4. Brazil Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.5.7. Argentina
        • 9.5.7.1. Argentina Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.5.7.2. Argentina Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.5.7.3. Argentina Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.5.7.4. Argentina Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.5.8. Rest of Latin America
        • 9.5.8.1. Rest of Latin America Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.5.8.2. Rest of Latin America Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.5.8.3. Rest of Latin America Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.5.8.4. Rest of Latin America Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
    • 9.6. Middle East & Africa
      • 9.6.1. Middle East & Africa Anthelmintic Drugs Market Revenue 2016 – 2026 (USD Million)
      • 9.6.2. Middle East & Africa Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
      • 9.6.3. Middle East & Africa Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
      • 9.6.4. Middle East & Africa Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
      • 9.6.5. Middle East & Africa Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.6.6. GCC Countries
        • 9.6.6.1. GCC Countries Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.6.6.2. GCC Countries Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.6.6.3. GCC Countries Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.6.6.4. GCC Countries Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.6.7. South Africa
        • 9.6.7.1. South Africa Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.6.7.2. South Africa Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.6.7.3. South Africa Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.6.7.4. South Africa Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
      • 9.6.8. Rest of MEA
        • 9.6.8.1. Rest of MEA Anthelmintic Drugs Market Revenue, by Drug Class, 2016 – 2026 (USD Million)
        • 9.6.8.2. Rest of MEA Anthelmintic Drugs Market Revenue, by Route of Administration, 2016 – 2026 (USD Million)
        • 9.6.8.3. Rest of MEA Anthelmintic Drugs Market Revenue, by Application, 2016 – 2026 (USD Million)
        • 9.6.8.4. Rest of MEA Anthelmintic Drugs Market Revenue, by Distribution Channel, 2016 – 2026 (USD Million)
  • Chapter 10. Company Profiles
    • 10.1. Novartis AG
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product portfulio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. *Same information will be provided for below mentioned companies*
      • 10.2.1. Cipla Inc.
      • 10.2.2. Sun Pharmaceutical Industries Ltd
      • 10.2.3. Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.)
      • 10.2.4. Zoetis, Inc.
      • 10.2.5. GlaxoSmithKline plc
      • 10.2.6. Bayer AG
      • 10.2.7. Merck & Co., Inc. (Intervet Inc.)
      • 10.2.8. Boehringer Ingelheim International GmbH
      • 10.2.9. Others

Methodology


Frequently Asked Questions

Effective use of anthelmintics in children is of significant public health interest since the parasites involved are likely to infect more than 2 billion people, most of whom are particularly prevalent and harmful in children. Properly targeted drug delivery, especially through community chemotherapy, can dramatically reduce aggregate mortality and morbidity as well as boost growth rates, physical activity and fitness, cognitive and academic performance and social well-being.

There are a variety of anthelmintics available for the management of gastrointestinal nematodes in cattle. Ostertagia ostertagi, lung worm, Fasciola hepatica, and Cooperia spp., are likely to cause the greatest losses in production in North America. Clorsulon is a fresh, safe anthelmintic that offers good control of the fluke of the liver and thus fills a void in control of cattle helminths in North America. The accurate use of anthelmintics in conjunction with management based on knowledge of parasite epidemiology will ensure that cattle are not easily reinfected. In this way, the advantages of the use of anthelmintics can be very substantial and much higher than the control costs.

According to Zion Market Research, the Anthelmintic Drugs market is expected to generate revenue of around USD 3,142.7 Million by the end of 2026, growing at a CAGR of 5.57%.

By Geography, the anthelmintic drugs market is segmented into North America, Europe, Latin America, Asia Pacific, and Middle East and Africa.

Europe accounted for the largest market for anthelmintic drugs in 2019, followed by Asia Pacific. The number of pet animals in the region is growing at a higher rate than that of livestock, leading to an increase in pet ownership, thereby the involvement of key players supplying anthelmintic drugs is also progressing. This, in turn, is expected to improve the growth of anthelmintic drugs market in the region.

The demand for anthelmintic drugs in Asia Pacific is likely to grow to the highest CAGR from 2020 to 2026. The growth of the market in the region can be attributed to a wide veterinary sector in China, New Zealand and Australia. Growing expenditure on pet care; increasing demand for animal care; and rising demand for veterinary hospitals and clinics in India, China, South Korea, and Hong Kong are some of the factors boosting the demand for anthelmintic drugs in the region

The major players in the global anthelmintic drugs market include Novartis AG, Cipla Inc., Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.), Zoetis, Inc., GlaxoSmithKline plc, Bayer AG, Merck & Co., Inc. (Intervet Inc.), and Boehringer Ingelheim International GmbH among others.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com